The effect of starting metformin on bone mineral density among women with type 2 diabetes in the Study of Women's Health Across the Nation (SWAN).
The effect of starting metformin on bone mineral density among women with type 2 diabetes in the Study of Women's Health Across the Nation (SWAN).
复制标题
在全国女性健康研究 (SWAN) 中，开始服用二甲双胍对 2 型糖尿病女性骨矿物质密度的影响。
DOI：
10.1007/s00198-023-06915-3
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Burnett-Bowie,Sherri-AnnM
中科院分区：
文献类型：
--
作者：
Solomon,DanielH;Ruppert,Kristine;Cauley,JaneA;Lian,Yinjuan;Altwies,Hallie;Shieh,Albert;Burnett-Bowie,Sherri-AnnM
我们研究了中年妇女开始二甲双胍治疗后BMD的纵向变化。研究受试者的平均年龄为57岁，36%为白色。开始二甲双胍治疗的女性与未开始二甲双胍治疗的女性相似。在3年的后续行动中，在所有解剖区域的BMD损失是相似的组之间和亚组，包括基线空腹blood glucose.Purpose/IntroductionWomen与2型糖尿病有较高的骨密度（BMD），经验较慢的BMD损失，但骨折的风险增加。关于二甲双胍对BMD影响的数据仍然不一致。我们研究了纵向变化的妇女在中年开始metformin.MethodsParticipants在全国妇女健康研究（SWAN），一个多样化的社区为基础的美国队列，与BMD测量进行了评估。倾向评分匹配有助于平衡二甲双胍启动者与非启动者的基线特征。混合模型回归测试组间BMD的变化。ResultsSubjects（n= 248）为57.4岁（平均值），35.9%为白色。开始二甲双胍治疗的女性（n= 124）与未开始二甲双胍治疗的女性（n= 124）在年龄和人种/种族方面相似。在中位3年随访期间，二甲双胍开始使用者和未使用者之间所有解剖区域的BMD损失相似（所有p> 0.3）。包括基线空腹血糖的亚组分析显示组间无差异。在围绝经期妇女开始二甲双胍（与不）与BMD changes.ConclusionsWomen在中年开始二甲双胍有纵向变化的BMD非常相似的其他妇女没有开始二甲双胍。
We examined longitudinal changes in BMD among women in the mid-life starting metformin. Study subjects were 57 years old (mean), and 36% were White. Women initiating metformin were similar to noninitiators. During the 3-year follow-up, BMD loss at all anatomic areas was similar between groups and in subgroups including baseline fasting blood glucose.Purpose/introductionWomen with type 2 diabetes have higher bone mineral density (BMD), experience slower BMD loss, but have increased fracture risk. Data regarding the effect of metformin on BMD remain discordant. We examined longitudinal changes in BMD among women in the mid-life starting metformin.MethodsParticipants in the Study of Women’s Health Across the Nation (SWAN), a diverse community-based US cohort, with BMD measurements were evaluated. Propensity score matching helped balance baseline characteristics of metformin initiators versus noninitiators. Mixed model regression tested the change in BMD between groups.ResultsSubjects (n= 248) were 57.4 years old (mean), and 35.9% were White. Women initiating metformin (n= 124) were similar to noninitiators (n= 124) in age and race/ethnicity. During the median 3-year follow-up, BMD loss at all anatomic areas was similar between the metformin initiators and nonusers (allp> 0.3). Subgroup analyses including baseline fasting blood glucose showed no between-group differences. Initiation of metformin (vs. not) in peri-menopausal women was not associated with BMD changes.ConclusionsWomen in the mid-life starting metformin had longitudinal changes in BMD very similar to other women not starting metformin.